Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium adolescentis CCFM1386
- Development stage
- Preclinical
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium adolescentis CCFM1386 is a probiotic bacterial strain developed by researchers at Jiangnan University's Culture Collection of Food Microorganisms (CCFM) in China. It is being investigated as a live biotherapeutic product for the treatment of prediabetes and related metabolic disorders. In preclinical studies using prediabetic mouse models, the strain has demonstrated the ability to significantly improve glucose tolerance, reduce serum insulin concentrations and insulin resistance, and lower LDL cholesterol levels. Its mechanism of action involves the restoration of gut microbiota structure and the promotion of beneficial metabolites, such as nicotinate and phenylalanine, which influence metabolic pathways including protein digestion and amino acid biosynthesis. The strain also exhibits protective effects on liver and pancreatic tissues.
- Other names
- 青春双歧杆菌CCFM1386Bifidobacterium adolescentis CCFM1386
Beyond the preview
Go deeper on bifidobacterium adolescentis CCFM1386.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium adolescentis CCFM1386.